Clinical Trial

Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopathy and provide a new method for the treatment of end-stage dilated cardiomyopathy.
Protocol Amendment History 4 changes
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
critical Trial completed 2026-04-07
notable Enrollment reduced: 9 -> 8 participants 2026-04-07
notable Primary completion moved earlier: 2026-03-30 -> 2025-10-12 2026-04-07
Trial Details
NCT Number NCT06902896
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Dilated Cardiomyopathy (DCM), Heart Failure
Enrollment 43 participants
Start Date 2025-04-22
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-14